Skip to main content
Journal cover image

Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.

Publication ,  Journal Article
Oyenuga, M; Halabi, S; Oyenuga, A; McSweeney, S; Morgans, AK; Ryan, CJ; Prizment, A
Published in: Prostate
May 2023

BACKGROUND: A prognostic risk score (Halabi score) in metastatic castration-resistant prostate cancer (mCRPC) accurately predicts overall survival, but its association with quality of life (QOL) has not been defined. We hypothesize that a higher pretreatment Halabi score is associated with worse QOL outcomes over time in mCRPC patients. METHODS: Patient-level data from the docetaxel plus prednisone control arm of Mainsail, a Phase 3 clinical trial in mCRPC were accessed via ProjectDataSphere. Pretreatment Halabi score included disease-related factors: metastatic site, opioid use, Eastern Cooperative Oncology Group performance status (ECOG-PS), alkaline phosphatase, albumin, hemoglobin, lactic acid dehydrogenase, and PSA, with higher score indicating worse survival. Three QOL scales were created: Functional Assessment of Cancer Therapy-Prostate (FACT-P, higher score = better QOL), Brief Pain Inventory-Short Form Severity score (BPI-SFSS, higher score = higher pain severity), and BPI-SF Interference score (BPI-SFIS, higher score = greater pain interference). Mixed linear model was used to estimate the associations between Halabi score and QOL scores assessed at different time points (baseline, 2 months, and 6 months). RESULTS: This analysis included 412 mCRPC patients (median age = 68 years, 82% white, 5% Black, median log PSA = 4.4 ng/mL). After multivariable adjustment, Halabi score was significantly associated with QOL scores at all time points. At 6 months, multivariable adjusted FACT-P decreased by 10.0 points (worsening), BPI-SFSS increased by 0.8 points (worsening), and BPI-SFIS increased by 0.9 points (worsening) for each unit increase in Halabi risk score. In multivariable analysis of individual components, ECOG-PS, site of metastasis, and opioid use were significantly associated with worse QOL scores at baseline. CONCLUSIONS: Chemotherapy-naïve mCRPC patients with poorer Halabi prognostic risk scores have poorer QOL and greater pain intensity and interference at baseline and during follow-up.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate

DOI

EISSN

1097-0045

Publication Date

May 2023

Volume

83

Issue

7

Start / End Page

688 / 694

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Quality of Life
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Prognosis
  • Prednisone
  • Pain
  • Oncology & Carcinogenesis
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Oyenuga, M., Halabi, S., Oyenuga, A., McSweeney, S., Morgans, A. K., Ryan, C. J., & Prizment, A. (2023). Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. Prostate, 83(7), 688–694. https://doi.org/10.1002/pros.24503
Oyenuga, Mosunmoluwa, Susan Halabi, Abayomi Oyenuga, Sean McSweeney, Alicia K. Morgans, Charles J. Ryan, and Anna Prizment. “Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.Prostate 83, no. 7 (May 2023): 688–94. https://doi.org/10.1002/pros.24503.
Oyenuga M, Halabi S, Oyenuga A, McSweeney S, Morgans AK, Ryan CJ, et al. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. Prostate. 2023 May;83(7):688–94.
Oyenuga, Mosunmoluwa, et al. “Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.Prostate, vol. 83, no. 7, May 2023, pp. 688–94. Pubmed, doi:10.1002/pros.24503.
Oyenuga M, Halabi S, Oyenuga A, McSweeney S, Morgans AK, Ryan CJ, Prizment A. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. Prostate. 2023 May;83(7):688–694.
Journal cover image

Published In

Prostate

DOI

EISSN

1097-0045

Publication Date

May 2023

Volume

83

Issue

7

Start / End Page

688 / 694

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Quality of Life
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Prognosis
  • Prednisone
  • Pain
  • Oncology & Carcinogenesis
  • Male
  • Humans